Immuno-Oncology

Johanna Bendell, MD, discusses the current and emerging treatment landscape of immunotherapy for patients with CRC.

The combination of cabiralizumab and nivolumab resulted in intriguing objective response rates in heavily pretreated patients with metastatic pancreatic cancer.

Neoadjuvant nivolumab plus ipilimumab demonstrated almost a tripling in objective response rate compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events for patients with high-risk resectable melanoma.

The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.

The combination of nivolumab and BMS-986205 generated promising response rates without increasing adverse effects in patients with advanced cervical or bladder cancers.

Nivolumab demonstrated a 24% overall response rate among patients with a range of non-colorectal cancers with mismatch repair deficiency who were identified through the NCI-MATCH trial.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

Immunotherapy is being positioned as an earlier therapeutic option for patients with high levels of microsatellite instability or mismatch repair deficiency, regardless of their tumor location, expert says.

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the future of immunotherapy combinations for patients with melanoma.

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center discusses biomarkers for immunotherapy in patients with bladder cancer.

A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.

Gerard Zalcman, MD, discusses the promise of immunotherapy in patients with mesothelioma.

Marina C. Garassino, MD, discusses the evolving paradigm of immunotherapy in NSCLC, with a specific focus on durvalumab and the role of combination therapy.

George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

Decades of clinical trials exploring modifications of cytotoxic regimens, including the use of different or more drugs, demonstrated that a therapeutic plateau had been reached with conventional chemotherapeutic agents, highlighting the need for novel approaches in urothelial carcinoma.

Andrea Apolo, MD, discusses the combination of cabozantinib plus nivolumab and ipilimumab, as well as the latest data on avelumab in urothelial carcinoma.

Nivolumab reduced the risk of death by 26% compared with everolimus in patients with previously treated advanced renal cell carcinoma.

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of pembrolizumab (Keytruda) for patients with endometrial cancer.

Sameh Mikhail, MD, medical oncologist, The Mark H. Zangmeister Cancer Center, discusses ongoing clinical trials for patients with myeloma.

In phase Ib results from the KEYNOTE-028 trial, pembrolizumab (Keytruda) was found to be active in cervical cancer while demonstrating safety results similar to previous studies with the PD-1 inhibitor.

The UK’s National Institute for Health and Care Excellence is recommending the use of atezolizumab for treatment-naïve patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-based therapy.

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in second-line bladder cancer treatment.

Merck has announced that it has withdrawn its European application for pembrolizumab in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer.

Howard "Skip" A. Burris, MD, discusses the ongoing research with PARP inhibitors and the advances in immunotherapy for patients with triple-negative breast cancer.

Jane N. Winter, MD, discusses immunotherapy in the treatment of patients with Hodgkin lymphoma.

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.

Denise A. Yardley, MD, discusses the promise of CDK4/6 inhibitors in estrogen receptor–positive breast cancer, and the potential with immunotherapy agents.

Paul A. Bunn Jr, MD, discusses strategies for analyzing and responding to signs of progression for patients receiving immunotherapy for non-small cell lung cancer.

Jane N. Winter, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses checkpoint inhibitors for Hodgkin lymphoma.